NEW YORK (360Dx) – Enzo Biochem and its subsidiary Enzo Life Sciences announced this week that the Patent Trial and Appeal Board has denied a petition filed by Hologic for inter partes review, a procedure for challenging the validity of patent claims, against US Patent 6,221,581. Enzo Life Sciences is asserting the patent in infringement litigation against Hologic, Grifols Diagnostic Solutions, and Grifols SA in the US District Court for the District of Delaware.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.